CYTK

CYTK

USD

Cytokinetics Incorporated Common Stock

$61.480+1.180 (1.957%)

Echtzeitkurs

Healthcare
Biotechnologie
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$60.300

Hoch

$61.480

Tief

$60.010

Volumen

1.92M

Unternehmensfundamentaldaten

Marktkapitalisierung

7.5B

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

2.29M

Börse

NMS

Währung

USD

52-Wochen-Spanne

Tief $29.31Aktuell $61.480Hoch $64.13

Ähnliche Nachrichten

Analyst Upgrades

B. Riley Securities Reiterates Buy on Cytokinetics, Raises Price Target to $90

B. Riley Securities analyst Mayank Mamtani reiterates Cytokinetics with a Buy and raises the price target from $80 to $90.

Mehr anzeigen
B. Riley Securities Reiterates Buy on Cytokinetics, Raises Price Target to $90
PR Newswire

Investors in Cytokinetics, Incorporated Should Contact The Gross Law Firm Before November 17, 2025 to Discuss Your Rights - CYTK

The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK). Shareholders who purchased shares of...

Mehr anzeigen
Investors in Cytokinetics, Incorporated Should Contact The Gross Law Firm Before November 17, 2025 to Discuss Your Rights - CYTK
GlobeNewswire

Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

Three Late Breaking Science Presentations from MAPLE-HCM Provide Additional Data Including Responder Analyses, Patient Reported Outcomes, and Cardiac Biomarkers SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE

Mehr anzeigen
Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025
PR Newswire

CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27,...

Mehr anzeigen
CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit
PR Newswire

CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27,...

Mehr anzeigen
CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit
GlobeNewswire

Cytokinetics to Participate in November Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that members of the Company management team will participate in the following investor conferences

PR Newswire

Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against...